A last-minute slide
Dr. Linda Kenney, a U.S. researcher, did not step in right away. She first asked how stable the pressure was, how oxygen concentration was controlled, and how safety limits and repeatability were ensured. After her session, she reviewed the pressure and oxygen records, checking that readings stayed consistent across uses. Satisfied, she added a new slide to her prepared talk, describing the combination of hyperbaric oxygen and lightweight design as a sample worth taking seriously for bringing aging interventions into practice through equipment.
The science behind the buzz
Hyperbaric oxygen is not new. In 2020, a Tel Aviv University study published in Aging followed 35 healthy adults over 64 who received three months of therapy at 2.0 ATA. Telomere length in their immune cells rose by an average of 38%, while the share of senescent cells fell by 11% to 37%. Harvard geneticist David Sinclair has called hyperbaric oxygen one of the most effective longevity approaches for cell repair and clearing aged cells. The trial was small, however, and larger studies are still needed.
A gap in the market
Western-made consumer chambers typically operate between 1.1 and 1.5 ATA, and hyperbaric medicine researchers note that devices below 1.5 ATA have not been shown to deliver effective intervention. The Chinese manufacturer’s chamber holds a stable 1.9 ATA while using aerospace-grade T700 carbon fiber, cutting weight by 60% compared with traditional steel units. That makes installation in ordinary buildings, including those with elevators, far more practical.
Leading longevity clinics in Switzerland and Hungary have adopted the equipment. The standard model is priced at 450,000 yuan and the premium version at 890,000 yuan, with waiting lists often stretching for months. The company runs more than 50 experience stores in China. Forum organizers said they chose it as the event’s only longevity-equipment supplier based on scientific evidence and verifiable technical parameters.
From molecules to maintenance
Longevity research has long focused on molecular targets, from screening drugs to boosting NAD+ and clearing senescent cells. The interest in oxygen chambers suggests another path. Rather than a new drug, a hyperbaric chamber reshapes the body’s environment through pressure, oxygen level and circulation. If such interventions can be standardized, measured and repeated, longevity may depend less on waiting for a “miracle pill” and more on treating the body as a system that needs regular, deep maintenance.
